Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4359 Treatment response and survival in 163 metastatic colorectal neuroendocrine carcinomas: A prospective cohort from the Nordic NEC registry

Introduction: Colorectal neuroendocrine carcinoma (CR-NEC) is a rare and aggressive disease. Most cases are metastatic at diagnosis and palliative chemotherapy is the only systemic treatment option.

Conference:

Presenting Author: Morken S

Authors: Morken S, Langer S, Knigge U, Hjortland G, Sundlöv A,

Keywords: neuroendocrine carcinoma, NEC, colorectal, chemotherapy,

#3717 Results of NETest liquid biopsy in high-grade gastroenteropancreatic neuroendocrine neoplasms

Introduction: Molecular blood biomarkers are lacking for high-grade (HG) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN), and morphologically separating between neuroendocrine carcinoma (NEC), neuroendocrine tumors (NET G3), adenocarcinoma and MINEN frequently difficult. The mRNA-based NETest has diagnostic, prognostic and predictive value in neuroendocrine tumors G1-2 but has not been studied in HG GEP-NEN.

Conference:

Presenting Author: Sorbye H

Authors: Sorbye H, Langer S, Hjortland G, Vestermark L, Sundlov A,

Keywords: NETest, high-grade, gastroenteropancreatic, neuroendocrine carcinoma, NET G3, neuroendocrine neoplasm, biomarker,

#3507 Phase II study of everolimus and temozolomide as 1-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms (NET G3 and NEC)

Introduction: High-grade gastroenteropancreatic neuroendocrine neoplasms (HG GEP-NEN) consist of poorly differentiated neuroendocrine carcinoma (NEC) and well-differentiated neuroendocrine tumors (NET G3). Platinum/etoposide has been the cornerstone of treatment in advanced cases, but show limited benefit for patients when tumors have Ki-67 ≤55%.

Conference:

Presenting Author:

Authors: Morken S, Langer S, Sundlöv A, Detlefsen S, Krogh M,

Keywords: neuroendocrine neoplasm, neuroendocrine carcinoma, high-grade gastroenteropancreatic, everolimus, temozolomide,

#2936 Mutational Landscape of 109 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms G3

Introduction: Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) G3 are rare with a poor outcome. Molecular data for GEP NEN G3 is limited and the 2019 WHO classification is based on morphology and proliferation rate.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Elvebakken H

Authors: Venizelos A, Elvebakken H, Perren A, Hjortland G, Sundlöv A,

Keywords: molecular genetics, neuroendocrine carcinoma, neuroendocrine tumors, gastroenteropancreatic, mutations,

#2025 Health-Related Quality of Life Determinants in Swedish Patients after Surgery for Small Intestinal Neuroendocrine Tumors

Introduction: Overall survival for patients with small intestinal neuroendocrine tumors (siNETs) is often long even with metastatic disease, making quality of life issues especially relevant. The impact of surgery on their quality of life is unknown.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Milanetto A, Nordenström E, Sundlöv A, Almquist M,

Keywords: health-related quality of life, small intestinal neuroendocrine tumor,